Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + ivonescimab
- Development stage
- Phase 2
- Lead developer
- Daiichi Sankyo
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Trastuzumab deruxtecan + ivonescimab is an investigational combination therapy comprising a HER2-directed antibody-drug conjugate (ADC) and a bispecific antibody. Trastuzumab deruxtecan (T-DXd) consists of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload (deruxtecan), designed to target and kill HER2-expressing tumor cells. Ivonescimab is a first-in-class bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), combining immunotherapy with anti-angiogenesis. This combination is being evaluated in Phase II clinical trials (e.g., the UNITY study) for patients with hormone receptor-positive (HR+), HER2-low or HER2-ultralow advanced breast cancer, including those with central nervous system (CNS) metastases.
- Other names
- Trastuzumab Deruxtecan and ivonescimabT-DXd + ivonescimab
02
Targets
CYP3A7 (Cytochrome P450 3A7)ERBB2 (Erb-b2 receptor tyrosine kinase 2)SLCO1B3 (Organic anion transporting polypeptide 1B3)ABCB1 (P-glycoprotein)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on trastuzumab deruxtecan + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + ivonescimab.